Biogen Inc. $BIIB Shares Sold by Horizon Investments LLC

Key Points

• Horizon Investments LLC cut its stake in Biogen by 71.5%, selling 43,667 shares in Q4 and now holds 17,382 shares valued at about $3.06 million, per its SEC filing.
• Biogen beat Q expectations with $3.57 EPS (vs. $2.95 expected) and set FY2026 guidance of 14.25–15.25 EPS, while analysts forecast roughly 15.24 EPS for the year.
• Several analysts raised price targets (e.g., Oppenheimer to $275, BMO to $196), but the consensus remains a Hold with an average target of $214.23.

Horizon Investments LLC decreased its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 71.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,382 shares of the biotechnology company's stock after selling 43,667 shares during the quarter. Horizon Investments LLC's holdings in Biogen were worth $3,059,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. One Wealth Advisors LLC acquired a new stake in shares of Biogen in the fourth quarter valued at about $282,000. Fifth Third Bancorp grew its position in shares of Biogen by 2.2% in the fourth quarter. Fifth Third Bancorp now owns 9,212 shares of the biotechnology company's stock valued at $1,621,000 after purchasing an additional 202 shares during the period. Danske Bank A S grew its position in shares of Biogen by 8.3% in the fourth quarter. Danske Bank A S now owns 48,415 shares of the biotechnology company's stock valued at $8,521,000 after purchasing an additional 3,705 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in Biogen during the fourth quarter worth about $530,000. Finally, Sigma Planning Corp acquired a new position in Biogen during the fourth quarter worth about $923,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BIIB. BMO Capital Markets boosted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a "market perform" rating in a research report on Friday, February 6th. Argus upgraded shares of Biogen to a "hold" rating in a research report on Thursday, April 9th. Oppenheimer boosted their price target on shares of Biogen from $250.00 to $275.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 1st. Citigroup boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Weiss Ratings upgraded shares of Biogen from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biogen currently has an average rating of "Hold" and an average target price of $214.23.

Biogen Price Performance

Shares of BIIB stock opened at $187.21 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm's 50-day moving average is $184.52 and its two-hundred day moving average is $176.50. Biogen Inc. has a 12 month low of $115.25 and a 12 month high of $202.41. The company has a market capitalization of $27.64 billion, a PE ratio of 20.09, a price-to-earnings-growth ratio of 1.53 and a beta of 0.19.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts' consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the firm earned $3.02 earnings per share. Biogen's quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts predict that Biogen Inc. will post 15.24 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company's stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is owned by company insiders.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.